Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL16506807 | 0.89 | TDP1 (0.40) | TDP1HSD17B10TSHRALDH1A1FFAR3 | |
| Methacrylic Acid SCHEMBL9681885 | 0.86 | TDP1 (0.40) | TDP1HSD17B10TSHRALDH1A1FFAR3 | |
| Methacrylic Acid SCHEMBL28229822 | 0.86 | TDP1 (0.44) | TDP1HSD17B10TSHRALDH1A1FFAR3 | |
| Methacrylic Acid SCHEMBL284735 | 0.86 | TDP1 (0.44) | TDP1HSD17B10TSHRALDH1A1FFAR3 | |
| Methacrylic Acid SCHEMBL27743356 | 0.84 | TDP1 (0.41) | TDP1TSHRALDH1A1FFAR3THRB | |
| Methacrylic Acid SCHEMBL15917025 | 0.83 | TDP1 (0.42) | TDP1HSD17B10TSHRALDH1A1FFAR3 | |
| Methacrylic Acid SCHEMBL1071243 | 0.83 | TDP1 (0.42) | TDP1HSD17B10TSHRALDH1A1FFAR3 | |
| Methacrylic Acid SCHEMBL28096441 | 0.83 | — | — | |
| Methacrylic Acid SCHEMBL1071245 | 0.83 | TDP1 (0.42) | TDP1HSD17B10TSHRALDH1A1FFAR3 | |
| Methacrylic Acid SCHEMBL7596069 | 0.83 | TDP1 (0.42) | TDP1HSD17B10TSHRALDH1A1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063351-A | Green synthesis of chiral beta amino acids using biological enzymes and immobilized aminotransferase used | 北京元延医药科技股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-4828840-A | Sustained-release formulation and production thereof | SHIONOGI & CO., LTD. (JP) | 1989-05-09 | — | — | US | claimed |
| CN-113194950-B | Treatment and prevention of premature ejaculation (PE) | 塞罗亚克PME贸易有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-11738064-B2 | Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused | ILDONG PHARM CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| US-20230093570-A1 | SOLID PREPARATION | SCREEN Holdings Co., Ltd. (JP) | 2023-03-23 | — | — | US | disclosed |
| CN-112451493-B | Abuse-preventing oxycodone oral sustained-release tablet and preparation method thereof | 江苏恩华药业股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-112402386-B | Abuse-preventing opioid oral sustained-release tablet and preparation method thereof | 江苏恩华药业股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-3973977-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED | Ildong Pharm Co., Ltd. (KR) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022029938-A1 | SKIN COMPOSITION | マルホ株式会社 | 2022-02-10 | — | — | WO | disclosed |
| CN-113194950-A | Treatment and prevention of Premature Ejaculation (PE) | 塞罗亚克PME贸易有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-112451493-A | Abuse-proof oxycodone oral sustained-release tablet and preparation method thereof | 江苏恩华药业股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-7956211-B2 | Trithiocarbonate derivatives and the use thereof in the form of transfer agents for acrylic acid controlled radical polymerisation | COATEX S.A.S. (FR) | 2011-06-07 | — | — | US | disclosed |
| US-20110033558-A1 | POLYMERS PRODUCED BY USING SULPHUR COMPOUNDS IN THE FORM OF TRANSFER AGENTS FOR CONTROLLED RADICAL POLYMERISATION OF ACRYLIC ACID AND THE USE THEREOF | COATEX S.A.S. (FR) | 2011-02-10 | — | — | US | disclosed |
| US-7851572-B2 | Polymers produced by using sulphur compounds in the form of transfer agents for controlled radical polymerisation of acrylic acid and the use thereof | COATEX S.A.S. (FR) | 2010-12-14 | — | — | US | disclosed |
| US-20070197747-A1 | Polymers Produced By Using Sulphur Compounds In The Form Of Transfer Agents For Controlled Radical Polymerisation Of Acrylic Acid And The Use Thereof | COATEX S.A.S. (FR) | 2007-08-23 | — | — | US | disclosed |
| US-20070179262-A1 | Trithiocarbonate derivatives and the use thereof in the form of transfer agents for acrylic acid controlled radical polymerisation | COATEX S.A.S. (FR) | 2007-08-02 | — | — | US | disclosed |
| EP-0807433-A1 | SUSTAINED-RELEASE PREPARATION | KANEBO LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0253684-B1 | SUBSTAINED-RELEASE FORMULATION AND PRODUCTION THEREOF | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4828840-A | Sustained-release formulation and production thereof | SHIONOGI & CO., LTD. (JP) | 1989-05-09 | — | — | US | disclosed |
| EP-0253684-A1 | Substained-release formulation and production thereof | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033558-A1 | POLYMERS PRODUCED BY USING SULPHUR COMPOUNDS IN THE FORM OF TRANSFER AGENTS FOR CONTROLLED RADICAL POLYMERISATION OF ACRYLIC ACID AND THE USE THEREOF | ASS1, HPRT1, GRHPR | TDP1 2466/4885HSD17B10 1908/4885TSHR 4236/4885 |
| US-20070179262-A1 | Trithiocarbonate derivatives and the use thereof in the form of transfer agents for acrylic acid controlled radical polymerisation | TST, AS3MT, TTPA | TDP1 1486/4885HSD17B10 2130/4885TSHR 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.